argenx Acquires Forte Biosciences for $2.2 Billion

Argenx has announced its acquisition of Forte Biosciences for approximately $2.2 billion, adding to its portfolio a promising anti-CD122 antibody program aimed at advancing treatments in autoimmune conditions. The move underscores Argenx's strategy of expanding its foothold in immunology through strategic acquisitions that complement its existing pipeline of innovative therapies.

Under the terms of the agreement, Argenx will purchase Forte Biosciences via a wholly owned subsidiary through an all-cash tender offer of $77 per share. This offer reflects a substantial 86% premium over Forte's recent average share price, following positive Phase Ib results in vitiligo. The acquisition does not require additional financing, as Argenx plans to fund the deal with cash reserves. Both corporate boards have approved the merger, which awaits customary closing conditions, including the expiration of the Hart-Scott-Rodino waiting period, and is anticipated to close by the third quarter of 2026.

The strategic acquisition primarily revolves around Forte's lead candidate, FB102. This first-in-class antibody has shown clinical effectiveness in Phase Ib trials for vitiligo and celiac disease, with further potential applications in other autoimmune disorders such as alopecia areata. Argenx views FB102 as a strategic fit with its immunology portfolio, which includes successful antibody treatments like efgartigimod. The acquisition aims to harness Forte's innovative science to address diseases that have seen limited therapeutic advancement.

The deal highlights the increasing activity in the biotechnology sector where companies strive to boost their innovative capabilities in autoimmune disease treatment. For Argenx, integrating Forte Biosciences’ assets reinforces its commitment to leadership in the immunology space. Competitors in the sector may feel pressure to pursue similar acquisitions or ramp up internal R&D efforts to keep pace with therapeutic advances.

Looking forward, the transaction's completion is contingent upon fulfilling typical regulatory conditions, including majority shareholder approval and compliance with antitrust regulations. The anticipated integration of Forte's technologies into Argenx's operations marks a significant step towards achieving its stated "Vision 2030" strategic goals, focusing on delivering innovative treatments across autoimmune conditions globally.